The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The reduced prognostic impact of the CLL-IPI in the new era of targeted agents
Inhye Ahn, MD, Dana-Farber Cancer Institute, Boston, MA, reflects on the diminishing impact of the chronic lymphocytic leukemia international prognostic index (CLL-IPI) in the new era of targeted agents. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
